Pre‐hospital thrombolysis for ST‐segment elevation myocardial infarction in regional Australia: long‐term follow up. Issue 6 (14th June 2020)

• Record Type: Journal Article
• Authors: Khan, Arshad A.; Williams, Trent; Al‐Omary, Mohamed S.; Feeney, Alex L.; Majeed, Tazeen; Savage, Lindsay; Stewart, Paul; Faddy, Steven; Collins, Nicholas J.; Fletcher, Peter; Boyle, Andrew J.
• Is Part Of: Internal medicine journal. Volume 50:Issue 6(2020)
• Page Start: 711
• Page End: 715
• Publication Date: 2020-06-14
• Subjects: ST‐segment elevation myocardial infarction -- pre‐hospital thrombolysis -- percutaneous coronary intervention; Medicine -- Periodicals; 616
• DOI: 10.1111/imj.14412
• Languages: English
• ISSNs: 1444-0903

Abstract

Abstract: Background: Delivering reperfusion therapy to patients with ST‐segment elevation myocardial infarction (STEMI) in regional areas without access to tertiary cardiology care remains challenging. The systems of care in Hunter New England Health, New South Wales, Australia (area covered = 130 000 km 2 ) to provide reperfusion to patients with STEMI involve a 12‐lead electrocardiogram in the ambulance, discussion between cardiologist and paramedic, followed by pre‐hospital thrombolysis (PHT) delivered in ambulance to appropriate patients >60 min from the cardiac catheterisation laboratories. Patients who can access the cardiac catheterisation laboratories within 60 min are treated with primary percutaneous coronary intervention (PCI). Aims: We have previously reported excellent 12‐month outcomes for patients receiving PHT and the aim of the current analysis is to look at the long term outcomes. Methods: We assessed long‐term all‐cause mortality and major adverse cardiovascular events of STEMI patients undergoing PHT in our health district from August 2008 to August 2013 and compared with the primary PCI group. Results: One hundred and fifty (mean age: 62 ± 13 years, males: 76%, n = 114) patients were administered PHT and 334 patients (mean age: 65 ± 13 years, males: 75%, n = 251) underwent primary PCI during the study period. During a median follow up of 6.2 years (interquartile range: 4.8–7.4 years) all‐cause mortality was 16% and 19% in the PHT and primary PCI groups respectively ( P = 0.4). Conclusion: Our real‐world experience shows that PHT followed by early transfer to a primary PCI‐capable centre is an effective reperfusion strategy, with comparable results to primary PCI, and mortality benefits are sustained to more than 6 years.